ClinicalTrials.gg
Active, not recruitingNCT03266874Updated Jun 25, 2025

G7 BiSpherical Acetabular Shell PMCF Study

An observational study in Rheumatoid Arthritis, Osteoarthritis and Noninflammatory Degenerative Joint Disease, sponsored by Zimmer Biomet. Active, not recruiting at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Zimmer Biomet · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 59 studies in Arthritis, Rheumatoid by Zimmer Biomet — 4 open to participants now, 22 under way, none of them phase 3. Arthritis, Rheumatoid · Zimmer Biomet.

Planned enrollment
16th of 34
160 · median 156
Started
2017
with 3 others
Observational
34 of 59
2 open now
Primary completion
2029-12
later than 12 of 21 live
Registered
26th of 59
by date

Among the 59 studies in Arthritis, Rheumatoid by Zimmer Biomet, this one is the 16th largest by planned enrollment of the 34 observational ones that give a count, is one of 4 that started in 2017, is one of 34 observational ones, reaches primary completion later than 12 of the 21 other live ones, and was the 26th registered.

Arthritis, Rheumatoid

3,332 studies on the registry are indexed under Arthritis, Rheumatoid; 443 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 59 studies in Arthritis, Rheumatoid by Zimmer Biomet are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Arthritis, Rheumatoid by Zimmer Biomet, or all of them as a file.
02

Study summary

The primary objective of this study is to obtain implant survivorship and clinical outcomes data for the commercially available G7 BiSpherical Acetabular Shell.

Read the detailed description

The G7 BiSpherical Acetabular Shell belongs to the G7 multi-bearing platform. It was developed to provide an additional surgical option for patients in need of a total hip replacement. The aim of the G7 BiSpherical Acetabular Shell is to increase hip function while reducing pain.

This study is a multicenter, prospective, non-randomized, non-controlled post market surveillance study involving orthopedic surgeons skilled in hip arthroplasty procedures. A minimum of 4 and a maximum of 5 sites will be involved in this study. This number of clinical centers will permit assessment of consistency among a multitude of investigators. 140-175 implants will be included into the study. Each site will be allowed to enroll 35 patients. All potential study subjects will be required to participate in the Informed Consent Process.

The safety and performance of the G7 BiSpherical Acetabular Shell will be assessed as following: implant survivorship based on revision with removal of the study device; safety based on incidence and frequency of adverse events; and clinical efficacy measured by overall pain and function, quality of life data and radiographic evaluation.

03

Conditions studied

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Noninflammatory Degenerative Joint Disease
  • Avascular Necrosis
  • Correction of Functional Deformity
  • Non-Union Fracture
  • Femoral Neck Fractures
  • Trochanteric Fractures

Keywords

  • total hip arthroplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients in need of a Total Hip Arthroplasty (primary or revision) which receive the G7 BiSperical Acetabular Shell and who meet all of the inclusion and none of the exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient capable of understanding the surgeon's explanations and following his instructions, able and willing to participate in the follow-up program and who gave consent to take part in the study.
  • Patient aged of 18 years or more whose skeleton reached bone maturity.
  • Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
  • Rheumatoid arthritis.
  • Correction of functional deformity.
  • Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques.
  • Revision procedures where other treatment or devices have failed.

Inclusion criteria specific for patients receiving the G7 BiSpherical Shell with the G7 Freedom Constrained Liner:

  • The Biomet G7 Freedom Constrained Liner is indicated for use as a component of a total hip prosthesis in primary and revision patients at high risk of dislocation due to a history of prior dislocation, bone loss, joint or soft tissue laxity, neuromuscular disease, or intraoperative instability, and for whom all other options to con-strained acetabular components have been considered.

Exclusion criteria

Exclusion Criteria:

Absolute exclusion criteria include:

  • Infection, sepsis, osteomyelitis.

Relative exclusion criteria include:

  • Uncooperative patient or patient with neurologic disorders who is incapable of following directions.
  • Osteoporosis.
  • Metabolic disorders which may impair bone formation.
  • Osteomalacia.
  • Distant foci of infections which may spread to the implant site.
  • Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram.
  • Vascular insufficiency, muscular atrophy or neuromuscular disease.
  • Patient unwilling or unable to give consent, or to comply with the follow-up program.
  • Patient known to be pregnant or breastfeeding.
  • Patient presenting any condition that would, in the judgment of the Investigator, place the patient at undue risk or interfere with the study.
  • Patient institutionalized or known drug abuser or alcoholic or anyone who cannot understand what is required of them.
  • Patient belonging to a vulnerable population.

Exclusion criteria specific for patients receiving the G7 BiSpherical Shell with the G7 Freedom Constrained Liner:

  • Bone or musculature compromised by disease, infection, or prior implantation that cannot provide adequate support or fixation for the prosthesis.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients who received the G7 BiSpherical Cup

    Subject in need of a THA who met the inclusion/exclusion criteria and received the G7 BiSpherical cup.

06

What researchers measure

Primary outcomes

  1. Implant survivorship is assessed counting the number of implant revisions

    Time frame: 10 years

Secondary outcomes

  1. Clinical efficacy of the device is assessed using the Oxford Hip Score patient questionnaire

    Time frame: 10 years

  2. Clinical efficacy of the device is assessed using the Harris Hip Score patient questionnaire

    Time frame: 10 years

  3. Safety is assessed according to the number of complications which are collected via adverse event forms.

    Time frame: 10 years

07

Study locations

5 sites
  • Cabinet du Dr. Miazzolo
    Perpignan, 66000, France
  • Orthopädische Chirurgie Müchen OCM
    Munich, Bavaria 81369, Germany
  • Herzogin Elisabeth Hospital
    Braunschweig, Lower Saxony 38124, Germany
  • Reinier de Graaf Groep
    Delft, Netherlands
  • Orthoprax AG
    Bern, 3012, Switzerland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2017 (actual). Primary completion is estimated for Dec 2029, 144 months after the start.

Of 155 industry-sponsored observational studies under Arthritis, Rheumatoid, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 116. This study's planned 144 months is above that.

Counting every sponsor, half of 389 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2017
First posted
Aug 30, 2017
StartActual
Dec 10, 2017
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2031
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03266874
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Aug 30, 2017
Start date
Dec 10, 2017
Primary completion
Dec 2029 (estimated)
Completion
Dec 2031 (estimated)
Last update
Jun 25, 2025

Study contacts

Hassan Achakri
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion